From Evidence-based Medicine to Marketing-based Medicine: Evidence from Internal Industry Documents

被引:71
作者
Spielmans, Glen I. [1 ]
Parry, Peter I. [2 ]
机构
[1] Metropolitan State Univ, Dept Psychol, St Paul, MN 55108 USA
[2] Flinders Univ S Australia, Dept Psychiat, Adelaide, SA, Australia
关键词
Evidence-based medicine; Marketing; Marketing-based medicine; Pharmaceutical industry; Olanzapine; Quetiapine; BIPOLAR DISORDER; PHARMACEUTICAL COMPANIES; AUTHORSHIP; PROMOTION; TRIALS; DEPRESSION; PREVALENCE; QUETIAPINE; ARTICLES; EFFICACY;
D O I
10.1007/s11673-010-9208-8
中图分类号
B82 [伦理学(道德学)];
学科分类号
摘要
While much excitement has been generated surrounding evidence-based medicine, internal documents from the pharmaceutical industry suggest that the publicly available evidence base may not accurately represent the underlying data regarding its products. The industry and its associated medical communication firms state that publications in the medical literature primarily serve marketing interests. Suppression and spinning of negative data and ghostwriting have emerged as tools to help manage medical journal publications to best suit product sales, while disease mongering and market segmentation of physicians are also used to efficiently maximize profits. We propose that while evidence-based medicine is a noble ideal, marketing-based medicine is the current reality.
引用
收藏
页码:13 / 29
页数:17
相关论文
共 90 条
[1]  
ALAM ESK, 2008, DISCUSSION DOCUMENT
[2]   Industry-sponsored clinical research - A broken system [J].
Angell, Marcia .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (09) :1069-1071
[3]  
APPLBAUM K, 2008, RETH EC ANTHR C JAN
[4]  
ARVANITIS L, 1997, WEIGHT GAIN
[5]  
*ASTRAZENECA, 2000, TD004 ASTRAZENECA
[6]  
*ASTRAZENECA, 2001, SER QUET SPEAK SLID
[7]  
AUBUCHON NW, 2002, RE REQUEST
[8]  
BAKER RW, 2000, M ENDOCRINOLOGIC CON
[9]  
BANDICK M, 2001, ZYPREXA PRIMARY CARE
[10]  
*BBC, 2007, PAN SECR DRUGS TRIAL